

SLEEPGABA 2(Eszopiclone Tablets 2mg)

1. Name of the finished pharmaceutical product

SLEEPGABA 2 (Eszopiclone Tablets 2mg)

2. Qualitative and quantitative composition

Each film coated tablet contains:

Eszopiclone 2 mg

Excipients: Lactose monohydrate

For the full list of excipients, see section 6.1.

3. Pharmaceutical form

Film coated tablet

White to off-white, round, biconvex, film-coated tablets debossed with 'H' on one side and 'E15' on the other side.

4. Clinical particulars

4.1 Therapeutic indications

Eszopiclone Tablets is indicated for the treatment of insomnia. In controlled outpatient and sleep laboratory studies, Eszopiclone Tablets administered at bedtime decreased sleep latency and improved sleep maintenance.

The clinical trials performed in support of efficacy were up to 6 months in duration. The final formal assessments of sleep latency and maintenance were performed at 4 weeks in the 6-week study (adults only), at the end of both 2-week studies (elderly only) and at the end of the 6month study (adults only).

4.2 Posology and method of administration Use the lowest effective dose for the patient.

4.2.1. Dosage in Adults

The recommended starting dose is 1 mg. Dosing can be raised to 2 mg or 3 mg if clinically indicated. In some patients, the higher morning blood levels of Eszopiclone Tablets following use of the 2 mg or 3 mg dose increase the risk of next day impairment of driving and other activities that require full alertness [see *Warnings and Precautions (5.1)*]. The total dose of Eszopiclone Tablets should not exceed 3 mg, once daily immediately before bedtime [see *Warnings and Precautions*].

4.2.2. Geriatric or Debilitated Patients

The total dose of Eszopiclone Tablets should not exceed 2 mg in elderly or debilitated patients. 4.2.3. Patients with Severe Hepatic Impairment, or Taking Potent CYP3A4 Inhibitors In patients with severe hepatic impairment, or in patients co-administered Eszopiclone Tablets with potent CYP3A4 inhibitors, the total dose of Eszopiclone Tablets should not exceed 2 mg [see *Warnings and Precautions*].

4.2.4. Use with CNS Depressants

Dosage adjustments may be necessary when Eszopiclone Tablets is combined with other central nervous system (CNS) depressant drugs because of the potentially additive effects [see *Warnings and Precautions*].

4.2.5. Administration with Food

Taking Eszopiclone Tablets with or immediately after a heavy, high-fat meal results in slower absorption and would be expected to reduce the effect of Eszopiclone Tablets on sleep latency [see *Clinical Pharmacology*].

4.3 Contraindications

Eszopiclone Tablets is contraindicated in patients who have experienced complex sleep behaviors after taking Eszopiclone Tablets [see *Warnings and Precautions*].

Eszopiclone Tablets is contraindicated in patients with known hypersensitivity to Eszopiclone. Hypersensitivity reactions include anaphylaxis and angioedema [see *Warnings and Precautions*].

4.4 Special warnings and precautions for use

Complex Sleep Behaviors

Complex sleep behaviors including sleep-walking, sleep-driving, and engaging in other activities while not fully awake may occur following the first or any subsequent use of Eszopiclone Tablets. Patients can be seriously injured or injure others during complex sleep behaviors. Such injuries may result in a fatal outcome. Other complex sleep behaviors (e.g., preparing and eating food, making phone calls, or having sex) have also been reported. Patients usually do not remember these events. Post-marketing reports have shown that complex sleep behaviors may occur with Eszopiclone Tablets

alone at recommended dosages, with or without the concomitant use of alcohol or other CNS depressants [see Drug Interactions]. Discontinue Eszopiclone Tablets immediately if a patient experiences a complex sleep behavior.

CNS Depressant Effects and Next-Day Impairment

Eszopiclone Tablets is a CNS depressant and can impair daytime function in some patients at the higher doses (2 mg or 3 mg), even when used as prescribed. Prescribers should monitor for excess depressant effects, but impairment can occur in the absence of symptoms (or even with subjective improvement), and impairment may not be reliably detected by ordinary clinical exam (i.e., less than formal psychomotor testing). While pharmacodynamic tolerance or adaptation to some adverse depressant effects of Eszopiclone Tablets may develop, patients using 3 mg Eszopiclone Tablets should be cautioned against driving or engaging in other hazardous activities or activities requiring complete mental alertness the day after use.

Additive effects occur with concomitant use of other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol), including daytime use. Downward dose adjustment of Eszopiclone Tablets and concomitant CNS depressants should be considered.

The use of Eszopiclone Tablets with other sedative-hypnotics at bedtime or the middle of the night is not recommended. The risk of next-day psychomotor impairment is increased if Eszopiclone Tablets is taken with less than a full night of sleep remaining (7- to 8 hours); if higher than the recommended dose is taken; if coadministered with other CNS depressants; or coadministered with other drugs that increase the blood levels of Eszopiclone

Because Eszopiclone Tablets can cause drowsiness and a decreased level of consciousness, patients, particularly the elderly, are at higher risk of falls.

Need to Evaluate for Comorbid Diagnoses

Because sleep disturbances may be the presenting manifestation of a physical and/or psychiatric disorder, symptomatic treatment of insomnia should be initiated only after a careful evaluation of the patient. The failure of insomnia to remit after 7 to 10 days of treatment may indicate the presence of a primary psychiatric and/or medical illness that should be evaluated. Worsening of insomnia or the emergence of new thinking or behavior abnormalities may be the consequence of an unrecognized psychiatric or physical disorder. Such findings have emerged during the course of treatment with sedative/hypnotic drugs, including Eszopiclone Tablets. Because some of the important adverse effects of Eszopiclone Tablets appear to be dose related, it is important to use the lowest possible effective dose, especially in the elderly.

Severe Anaphylactic and Anaphylactoid Reactions

Rare cases of angioedema involving the tongue, glottis or larynx have been reported in patients after taking the first or subsequent doses of sedative-hypnotics, including Eszopiclone Tablets. Some patients have had additional symptoms such as dyspnea, throat closing, or nausea and vomiting that suggest anaphylaxis. Some patients have required medical therapy in the emergency department. If angioedema involves the tongue, glottis or larynx, airway obstruction may occur and be fatal. Patients who develop angioedema after treatment with Eszopiclone Tablets should not be rechallenged with the drug.

Abnormal Thinking and Behavioral Changes

A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of sedative/hypnotics. Some of these changes may be characterized by decreased inhibition (e.g., aggressiveness and extroversion that seem out of character), similar to effects produced by alcohol and other CNS depressants. Other reported behavioral changes have included bizarre behavior, agitation, hallucinations, and depersonalization. Amnesia and other neuropsychiatric symptoms may occur unpredictably.

It can rarely be determined with certainty whether a particular instance of the abnormal behaviors listed above is drug induced, spontaneous in origin, or a result of an underlying psychiatric or physical disorder. Nonetheless, the emergence of any new behavioral sign or symptom of concern requires careful and immediate evaluation.

Withdrawal Effects

Following rapid dose decrease or abrupt discontinuation of the use of sedative/hypnotics, there have been reports of signs and symptoms similar to those associated with withdrawal from other CNS-depressant drugs [see Drug Abuse and Dependence].

Timing of Drug Administration

Eszopiclone Tablets should be taken immediately before bedtime. Taking a sedative/hypnotic while still up and about may result in short-term memory impairment, hallucinations, impaired coordination, dizziness, and lightheadedness.

Special Populations

Use in Elderly and/or Debilitated Patients

Impaired motor and/or cognitive performance after repeated exposure or unusual sensitivity to sedative/hypnotic drugs is a concern in the treatment of elderly and/or debilitated patients. The dose should not exceed 2 mg in elderly or debilitated patients.

Use in Patients with Concomitant Illness

Clinical experience with Eszopiclone in patients with concomitant illness is limited. Eszopiclone should be used with caution in patients with diseases or conditions that could affect metabolism or hemodynamic responses.

A study in healthy volunteers did not reveal respiratory-depressant effects at doses 2.5-fold higher (7 mg) than the recommended dose of Eszopiclone. Caution is advised, however, if Eszopiclone Tablets is prescribed to patients with compromised respiratory function.

The dose of Eszopiclone Tablets should not exceed 2 mg in patients with severe hepatic impairment, because systemic exposure is doubled in such subjects. No dose adjustment appears necessary for subjects with mild or moderate hepatic impairment. No dose adjustment appears necessary in subjects with any degree of renal impairment, since less than 10% of Eszopiclone is excreted unchanged in the urine.

The dose of Eszopiclone Tablets should be reduced in patients who are administered potent inhibitors of CYP3A4, such as ketoconazole, while taking Eszopiclone Tablets. Downward dose adjustment is also recommended when Eszopiclone Tablets is administered with agents having known CNS-depressant effects.

Use in Patients with Depression

In primarily depressed patients treated with sedative-hypnotics, worsening of depression, including suicidal thoughts and actions (including completed suicides), have been reported in association with the use of sedative/hypnotics. Sedative/hypnotic drugs should be administered with caution to patients exhibiting signs and symptoms of depression. Suicidal tendencies may be present in such patients, and protective measures may be required. Intentional overdose is more common in this group of patients; therefore, the least amount of drug that is feasible should be prescribed for the patient at any one time.

4.5 Interaction with other medicinal products and other forms of interaction CNS Active Drugs

Ethanol: An additive effect on psychomotor performance was seen with coadministration of Eszopiclone and ethanol [see Warnings and Precautions].

Olanzapine: Coadministration of Eszopiclone and olanzapine produced a decrease in DSST scores. The interaction was pharmacodynamic; there was no alteration in the pharmacokinetics of either drug.

Drugs that Inhibit or Induce CYP3A4

Drugs that Inhibit CYP3A4 (Ketoconazole)

CYP3A4 is a major metabolic pathway for elimination of Eszopiclone. The exposure of Eszopiclone was increased by coadministration of ketoconazole, a potent inhibitor of CYP3A4. Other strong inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, nefazodone, troleandomycin, ritonavir, nelfinavir) would be expected to behave similarly. Dose reduction of Eszopiclone Tablets is needed for patient co-administered Eszopiclone Tablets with potent CYP3A4 inhibitors [see Dosage and Administration].

Drugs that Induce CYP3A4 (Rifampicin)

Racemic Eszopiclone exposure was decreased 80% by concomitant use of rifampicin, a potent inducer of CYP3A4. A similar effect would be expected with Eszopiclone. Combination use with CYP3A4 inducer may decrease the exposure and effects of Eszopiclone Tablets.

4.6 Special population

Pregnancy

Risk Summary

Available pharmacovigilance data with Eszopiclone Tablets use in pregnant women are insufficient to identify a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. In animal reproduction studies conducted in pregnant rats and rabbits throughout organogenesis, there was no evidence of teratogenicity. Administration of Eszopiclone to rats throughout pregnancy and lactation resulted in offspring toxicities at all doses tested; the lowest dose was approximately 200 times the maximum recommended human dose (MRHD) of 3 mg/day based on mg/m² body surface area.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. **Lactation**

Risk Summary

There are no data on the presence of Eszopiclone in either human or animal milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Eszopiclone Tablets and any potential adverse effects on the breastfed infant from Eszopiclone Tablets or from the underlying maternal condition.

Pediatric Use

Safety and effectiveness of Eszopiclone Tablets have not been established in pediatric patients. Eszopiclone Tablets failed to demonstrate efficacy in controlled clinical studies of pediatric patients with Attention-Deficit/Hyperactivity (ADHD) associated insomnia.

In a 12-week controlled study, 483 pediatric patients (aged 6-17 years) with insomnia associated with ADHD (with 65% of the patients using concomitant ADHD treatments) were treated with oral tablets of Eszopiclone Tablets (1, 2 or 3 mg tablets, n=323), or placebo (n=160). Eszopiclone Tablets did not significantly decrease latency to persistent sleep, compared to placebo, as measured by polysomnography after 12 weeks of treatment. Psychiatric and nervous system disorders comprised the most frequent treatment-emergent adverse reactions observed with Eszopiclone Tablets versus placebo and included dysgeusia (9% vs. 1%), dizziness (6% vs. 2%), hallucinations (2% vs. 0%) and suicidal ideation (0.3% vs. 0%). Nine patients on Eszopiclone Tablets (3%) discontinued treatment due to an adverse reaction compared to 3 patients on placebo (2%).

In studies in which Eszopiclone (2 to 300 mg/kg/day) was orally administered to young rats from weaning through sexual maturity, neurobehavioral impairment (altered auditory startle response) and reproductive toxicity (adverse effects on male reproductive organ weights and histopathology) were observed at doses ≥5 mg/kg/day. Delayed sexual maturation was noted in males and females at ≥10 mg/kg/day. The no-effect dose (2 mg/kg) was associated with plasma exposures (AUC) for Eszopiclone and metabolite (S)-desmethylzopEszopiclone [(S)DMZ] approximately 2 times plasma exposures in humans at the MRHD in adults (3 mg/day). When Eszopiclone (doses from 1 to 50 mg/kg/day) was orally administered to young dogs from weaning through sexual maturity, neurotoxicity (convulsions) was observed at doses ≥ 5 mg/kg/day. Hepatotoxicity (elevated liver enzymes and hepatocellular vacuolation and degeneration) and reproductive toxicity (adverse effects on male reproductive organ weights and histopathology) were noted at doses ≥10 mg/kg/day. The no-effect dose (1 mg/kg) was associated with plasma exposures (AUC) to Eszopiclone and (S)-DMZ approximately 3 and 2 times, respectively, plasma exposures in humans at the MRHD in adults. **Geriatric Use**

A total of 287 subjects in double-blind, parallel-group, placebo-controlled clinical trials who received Eszopiclone were 65 to 86 years of age. The overall pattern of adverse events for elderly subjects (median age = 71 years) in 2-week studies with nighttime dosing of 2 mg Eszopiclone was not different from that seen in younger adults [see Adverse Reactions]. Eszopiclone Tablets 2 mg exhibited significant reduction in sleep latency and improvement in sleep maintenance in the elderly population. Compared with nonelderly adults, subjects 65 years and older had longer elimination and higher total exposure to Eszopiclone. Therefore, dose reduction is recommended in elderly patients [see Clinical Pharmacology].

Hepatic Impairment

No dose adjustment is necessary for patients with mild-to-moderate hepatic impairment. Exposure was increased in severely impaired patients compared with healthy volunteers. The dose of Eszopiclone Tablets should not exceed 2 mg

in patients with severe hepatic impairment. Eszopiclone Tablets should be used with caution in patients with hepatic impairment [see Clinical Pharmacology].

4.7 Effects on ability to drive and use machines

Eszopiclone tablets has no influence on the ability to drive and use machines.

4.8 Undesirable effects

The following are described in more detail in the Warnings and Precautions section of the label:

- Complex Sleep Behaviours
- CNS Depressant Effects and Next-Day
- Need to Evaluate for Comorbid Diagnoses
- Severe Anaphylactic and Anaphylactoid Reactions
- Abnormal Thinking and Behavioural Changes
- Withdrawal Effects
- Timing of Drug Administration
- Special Populations

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The premarketing development program for Eszopiclone Tablets included Eszopiclone exposures in patients and/or normal subjects from two different groups of studies: approximately 400 normal subjects in clinical pharmacology/pharmacokinetic studies, and approximately 1550 patients in placebo-controlled clinical effectiveness studies, corresponding to approximately 263 patient-exposure years. The conditions and duration of treatment with Eszopiclone Tablets varied greatly and included (in overlapping categories) open-label and double-blind phases of studies, inpatients and outpatients, and short-term and longer-term exposure. Adverse reactions were assessed by collecting adverse events, results of physical examinations, vital signs, weights, laboratory analyses, and ECGs.

The stated frequencies of adverse reactions represent the proportion of individuals who experienced, at least once, adverse reaction of the type listed. A reaction was considered treatment-emergent if it occurred for the first time or worsened while the patient was receiving therapy following baseline evaluation.

Clinical Trials Experience

Adverse Reactions Resulting in Discontinuation of Treatment

In placebo-controlled, parallel-group clinical trials in the elderly, 3.8% of 208 patients who received placebo, 2.3% of 215 patients who received 2 mg Eszopiclone Tablets, and 1.4% of 72 patients who received 1 mg Eszopiclone Tablets discontinued treatment due to an adverse reaction. In the 6-week parallel-group study in adults, no patients in the 3 mg arm discontinued because of an adverse reaction. In the long-term 6-month study in adult insomnia patients, 7.2% of 195 patients who received placebo and 12.8% of 593 patients who received 3 mg Eszopiclone Tablets discontinued due to an adverse reaction. No reaction that resulted in discontinuation occurred at a rate of greater than 2%.

Adverse Reactions Observed at an Incidence of ≥2% in Controlled Trials

TABLE 1 shows the incidence of adverse reactions from a Phase 3 placebo-controlled study of Eszopiclone Tablets at doses of 2 or 3 mg in nonelderly adults. Treatment duration in this trial was 44 days. The table includes only reactions that occurred in 2% or more of patients treated with Eszopiclone Tablets 2 mg or 3 mg in which the incidence in patients treated with Eszopiclone Tablets was greater than the incidence in placebo-treated patients.

Table 1: Incidence (%) of Adverse Reactions in a 6-Week Placebo-Controlled Study in Nonelderly Adults with Eszopiclone Tablets 1mg.

Adverse Reaction	Placebo (n=99)	Eszopiclone Tablets 2 mg (n=104)	Eszopiclone Tablets 3 mg (n=105)
Body as a Whole			
Headache	13	21	17
Viral Infection	1	3	3
Digestive System			
Dry Mouth	3	5	7

Dyspepsia	4	4	5
Nausea	4	5	4
Vomiting	1	3	0
Nervous System			
Anxiety	0	3	1
Confusion	0	0	3
Depression	0	4	1
Dizziness	4	5	7
Hallucinations	0	1	3
Libido Decreased	0	0	3
Nervousness	3	5	0
Somnolence	3	10	8
Respiratory System			
Infection	3	5	10
Skin and Appendages			
Rash	1	3	4
Special Senses			
Unpleasant Taste	3	17	34
Urogenital System			
Dysmenorrhea *	0	3	0
Gynecomastia **	0	3	0

Reactions for which the Eszopiclone Tablets incidence was equal to or less than placebo are not listed on the table, but included the following: abnormal dreams, accidental injury, back pain, diarrhea, flu syndrome, myalgia, pain, pharyngitis, and rhinitis.

* Gender-specific adverse reaction in females

** Gender-specific adverse reaction in males

Adverse reactions from Table 1 that suggest a dose-response relationship in adults include viral infection, dry mouth, dizziness, hallucinations, infection, rash, and unpleasant taste, with this relationship clearest for unpleasant taste.

TABLE 2 shows the incidence of adverse reactions from combined Phase 3 placebo-controlled studies of Eszopiclone Tablets at doses of 1 or 2 mg in elderly adults (ages 65-86). Treatment duration in these trials was 14 days. The table includes only reactions that occurred in 2% or more of patients treated with Eszopiclone Tablets 1 mg or 2 mg in which the incidence in patients treated with Eszopiclone Tablets was greater than the incidence in placebo-treated patients.

Table 2: Incidence (%) of Adverse Reactions in Elderly Adults (Ages 65-86 Years) in 2Week Placebo-Controlled Trials with Eszopiclone Tablets 1 mg.

Adverse Reactions	Placebo (n=208)	Eszopiclone Tablets 1 mg (n=72)	Eszopiclone Tablets 2 mg (n=215)
Body as a Whole			
Accidental Injury	1	0	3
Headache	14	15	13
Pain	2	4	5
Digestive System			
Diarrhea	2	4	2
Dry Mouth	2	3	7
Dyspepsia	2	6	2
Nervous System			
Abnormal Dreams	0	3	1
Dizziness	2	1	6

Nervousness	1	0	2
Neuralgia	0	3	0
Skin and Appendages			
Pruritus	1	4	1
Special Senses			
Unpleasant Taste	0	8	12
Urogenital System			
Urinary Tract Infection	0	3	0

Reactions for which the Eszopiclone Tablets incidence was equal to or less than placebo are not listed on the table, but included the following: abdominal pain, asthenia, nausea, rash, and somnolence.

Adverse reactions from Table 2 that suggest a dose-response relationship in elderly adults include pain, dry mouth, and unpleasant taste, with this relationship again clearest for unpleasant taste.

These figures cannot be used to predict the incidence of adverse reactions in the course of usual medical practice because patient characteristics and other factors may differ from those that prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. The cited figures, however, do provide the prescribing physician with some basis for estimating the relative contributions of drug and nondrug factors to the adverse reaction incidence rate in the population studied.

Other Reactions Observed During the Premarketing Evaluation of Eszopiclone Tablets Following is a list of modified COSTART terms that reflect adverse reactions as defined in the introduction to the ADVERSE REACTIONS section and reported by approximately 1550 subjects treated with Eszopiclone Tablets at doses in the range of 1 to 3.5 mg/day during Phase 2 and 3 clinical trials throughout the United States and Canada. All reported reactions are included except those already listed in Tables 1 and 2 or elsewhere in labeling, minor reactions common in the general population, and reactions unlikely to be drug related. Although the reactions reported occurred during treatment with Eszopiclone Tablets, they were not necessarily caused by it.

Reactions are further categorized by body system and listed in order of decreasing frequency according to the following definitions: frequent adverse reactions are those that occurred on one or more occasions in at least 1/100 patients; infrequent adverse reactions are those that occurred in fewer than 1/100 patients but in at least 1/1,000 patients; rare adverse reactions are those that occurred in fewer than 1/1,000 patients. Gender-specific reactions are categorized based on their incidence for the appropriate gender.

Body as a Whole: Frequent: chest pain; Infrequent: allergic reaction, cellulitis, face edema, fever, halitosis, heat stroke, hernia, malaise, neck rigidity, photosensitivity.

Cardiovascular System: Frequent: migraine; Infrequent: hypertension; Rare: thrombophlebitis.

Digestive System: Infrequent: anorexia, cholelithiasis, increased appetite, melena, mouth ulceration, thirst, ulcerative stomatitis; Rare: colitis, dysphagia, gastritis, hepatitis, hepatomegaly, liver damage, stomach ulcer, stomatitis, tongue edema, rectal hemorrhage.

Hemic and Lymphatic System: Infrequent: anemia, lymphadenopathy.

Metabolic and Nutritional: Frequent: peripheral edema; Infrequent: hypercholesteremia, weight gain, weight loss; Rare: dehydration, gout, hyperlipemia, hypokalemia.

Musculoskeletal System: Infrequent: arthritis, bursitis, joint disorder (mainly swelling, stiffness, and pain), leg cramps, myasthenia, twitching; Rare: arthrosis, myopathy, ptosis. **Nervous System: Infrequent:** agitation, apathy, ataxia, emotional lability, hostility, hypertonia, hypesthesia, incoordination, insomnia, memory impairment, neurosis, nystagmus, paresthesia, reflexes decreased, thinking abnormal (mainly difficulty concentrating), vertigo; Rare: abnormal gait, euphoria, hyperesthesia, hypokinesia, neuritis, neuropathy, stupor, tremor. **Respiratory System:** Infrequent: asthma, bronchitis, dyspnea, epistaxis, hiccup, laryngitis. **Skin and Appendages:** Infrequent: acne, alopecia, contact dermatitis, dry skin, eczema, skin discoloration, sweating, urticaria; Rare: erythema multiforme, furunculosis, herpes zoster, hirsutism, maculopapular rash, vesiculobullous rash.

Special Senses: Infrequent: conjunctivitis, dry eyes, ear pain, otitis externa, otitis media, tinnitus, vestibular disorder; Rare: hyperacusis, iritis, mydriasis and photophobia.

Urogenital System: Infrequent: amenorrhea, breast engorgement, breast enlargement, breast neoplasm, breast pain, cystitis, dysuria, female lactation, hematuria, kidney calculus, kidney pain, mastitis, menorrhagia, metrorrhagia, urinary frequency, urinary incontinence, uterine hemorrhage, vaginal hemorrhage, vaginitis; Rare: oliguria, pyelonephritis, urethritis. **Postmarketing Experience**

In addition to the adverse reactions observed during clinical trials, dysosmia, an olfactory dysfunction that is characterized by distortion of the sense of smell, has been reported during postmarketing surveillance with Eszopiclone Tablets. Because this event is reported spontaneously from a population of unknown size, it is not possible to estimate the frequency of this event.

Reporting of suspected adverse reactions: Healthcare professionals are requested to report any suspected adverse reactions via pharmacy and poisons board, Pharmacovigilance Reporting System (PvERS) <https://pv.pharmacyboardkenya.org>

4.9 Overdose

In clinical trials with Eszopiclone, one case of overdose with up to 36 mg of Eszopiclone was reported in which the subject fully recovered. Since commercial marketing began, spontaneous cases of Eszopiclone overdoses up to 270 mg (90 times the maximum recommended dose of Eszopiclone) have been reported, in which patients have recovered. Fatalities related to Eszopiclone Tablets overdoses were reported only in combination with other CNS drugs or alcohol.

Signs and Symptoms

Signs and symptoms of overdose effects of CNS depressants can be expected to present as exaggerations of the pharmacological effects noted in preclinical testing. Impairment of consciousness ranging from somnolence to coma has been described. Rare individual instances of fatal outcomes following overdose with racemic Eszopiclone have been reported in European postmarketing reports, most often associated with overdose with other CNSdepressant agents. Methemoglobinemia in association with overdoses of racemic Eszopiclone has been reported.

Recommended Treatment

General symptomatic and supportive measures should be used along with immediate gastric lavage where appropriate. Intravenous fluids should be administered as needed. Flumazenil may be useful. As in all cases of drug overdose, respiration, pulse, blood pressure, and other appropriate signs should be monitored and general supportive measures employed. Hypotension and CNS depression should be monitored and treated by appropriate medical intervention. Consider monitoring methemoglobin in the setting of high-dose overdosage. The value of dialysis in the treatment of overdosage has not been determined.

As with the management of all overdosage, the possibility of multiple drug ingestion should be considered. The physician may wish to consider contacting a poison control center for up-to-date information on the management of hypnotic drug product overdosage.

5.0 Pharmacological properties

5.1 Pharmacodynamic properties

Mechanism of Action

The mechanism of action of Eszopiclone as a hypnotic is unclear; however, its effect could be related to its interaction with GABA-receptor complexes at binding domains located close to or allosterically coupled to benzodiazepine receptors.

5.2 Pharmacokinetic properties

The pharmacokinetics of Eszopiclone have been investigated in healthy subjects (adult and elderly) and in patients with hepatic disease or renal disease. In healthy subjects, the pharmacokinetic profile was examined after single doses of up to 7.5 mg and after once-daily administration of 1, 3, and 6 mg for 7 days. Eszopiclone is rapidly absorbed, with a time to peak concentration (t_{max}) of approximately 1 hour and a terminal-phase elimination half-life (t_{1/2}) of approximately 6 hours. In healthy adults, Eszopiclone Tablets does not accumulate with once-daily administration, and its exposure is dose-proportional over the range of 1 to 6 mg.

Absorption and Distribution

Eszopiclone is rapidly absorbed following oral administration. Peak plasma concentrations are achieved within approximately 1 hour after oral administration. Eszopiclone is weakly bound to plasma protein (52-59%). The large free

fraction suggests that Eszopiclone disposition should not be affected by drug-drug interactions caused by protein binding. The blood-toplasma ratio for Eszopiclone is less than one, indicating no selective uptake by red blood cells.

Metabolism

Following oral administration, Eszopiclone is extensively metabolized by oxidation and demethylation. The primary plasma metabolites are (S)-zopEszopiclone-N-oxide and (S)-Ndesmethyl zopEszopiclone; the latter compound binds to GABA receptors with substantially lower potency than Eszopiclone, and the former compound shows no significant binding to this receptor. In vitro studies have shown that CYP3A4 and CYP2E1 enzymes are involved in the metabolism of Eszopiclone. Eszopiclone did not show any inhibitory potential on CYP450 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 in cryopreserved human hepatocytes.

Elimination

After oral administration, Eszopiclone is eliminated with a mean $t_{1/2}$ of approximately 6 hours. Up to 75% of an oral dose of racemic Eszopiclone is excreted in the urine, primarily as metabolites. A similar excretion profile would be expected for Eszopiclone, the S-isomer of racemic Eszopiclone. Less than 10% of the orally administered Eszopiclone dose is excreted in the urine as parent drug.

Effect of Food

In healthy adults, administration of a 3 mg dose of Eszopiclone after a high-fat meal resulted in no change in AUC, a reduction in mean C_{max} of 21%, and delayed t_{max} by approximately 1 hour. The half-life remained unchanged, approximately 6 hours. The effects of Eszopiclone Tablets on sleep onset may be reduced if it is taken with or immediately after a high-fat/heavy meal.

Specific Populations

Age

Compared with nonelderly adults, subjects 65 years and older had an increase of 41% in total exposure (AUC) and a slightly prolonged elimination of Eszopiclone ($t_{1/2}$ approximately 9 hours). C_{max} was unchanged. Therefore, in elderly patients the dose should not exceed 2 mg.

Gender

The pharmacokinetics of Eszopiclone in men and women are similar. *Race*

In an analysis of data on all subjects participating in Phase 1 studies of Eszopiclone, the pharmacokinetics for all races studied appeared similar. *Hepatic Impairment*

Pharmacokinetics of a 2 mg Eszopiclone dose were assessed in 16 healthy volunteers and in 8 subjects with mild, moderate, and severe liver disease. Exposure was increased 2-fold in severely impaired patients compared with the healthy volunteers. C_{max} and t_{max} were unchanged. No dose adjustment is necessary for patients with mild-to-moderate hepatic impairment. Dose reduction is recommended for patients with severe hepatic impairment. Eszopiclone Tablets should be used with caution in patients with hepatic impairment *Renal Impairment*

The pharmacokinetics of Eszopiclone were studied in 24 patients with mild, moderate, or severe renal impairment. AUC and C_{max} were similar in the patients compared with demographically matched healthy control subjects. No dose adjustment is necessary in patients with renal impairment, since less than 10% of the orally administered Eszopiclone dose is excreted in the urine as parent drug.

Drug Interactions

Eszopiclone is metabolized by CYP3A4 and CYP2E1 via demethylation and oxidation. There were no pharmacokinetic or pharmacodynamic interactions between Eszopiclone and paroxetine. When Eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of Eszopiclone or olanzapine, but a pharmacodynamic interaction was seen on a measure of psychomotor function. Eszopiclone and lorazepam decreased each other's C_{max} by 22%. Coadministration of Eszopiclone 3 mg to subjects receiving ketoconazole, a potent inhibitor of CYP3A4, 400 mg daily for 5 days, resulted in a 2.2-fold increase in exposure to Eszopiclone. C_{max} and $t_{1/2}$ were increased 1.4-fold and 1.3fold, respectively. Eszopiclone Tablets would not be expected to alter the clearance of drugs metabolized by common CYP450 enzymes [see Warnings and Precautions].

Paroxetine: Coadministration of single dose of Eszopiclone and paroxetine produced no pharmacokinetic or pharmacodynamic interaction. The lack of a drug interaction following single-dose administration does not predict the complete absence of a pharmacodynamic effect following chronic administration.

Lorazepam: Coadministration of single doses of Eszopiclone and lorazepam did not have clinically relevant effects on the pharmacodynamics or pharmacokinetics of either drug. The lack of a drug interaction following single-dose administration does not predict the complete absence of a pharmacodynamic effect following chronic administration.

Drugs with a Narrow Therapeutic Index

Digoxin: A single dose of Eszopiclone 3 mg did not affect the pharmacokinetics of digoxin measured at steady state following dosing of 0.5 mg twice daily for one day and 0.25 mg daily for the next 6 days.

Warfarin: Eszopiclone 3 mg administered daily for 5 days did not affect the pharmacokinetics of (R)- or (S)-warfarin, nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of warfarin.

Drugs Highly Bound to Plasma Protein

Eszopiclone is not highly bound to plasma proteins (52-59% bound); therefore, the disposition of Eszopiclone is not expected to be sensitive to alterations in protein binding. Administration of Eszopiclone 3 mg to a patient taking another drug that is highly protein-bound would not be expected to cause an alteration in the free concentration of either drug.

5.3 Clinical safety data

The effect of Eszopiclone Tablets on reducing sleep latency and improving sleep maintenance was established in studies with 2100 subjects (ages 18-86) with chronic and transient insomnia in six placebo-controlled trials of up to 6 months' duration. Two of these trials were in elderly patients (n=523). Overall, at the recommended adult dose (2-3 mg) and elderly dose (1-2 mg), Eszopiclone Tablets significantly decreased sleep latency and improved measures of sleep maintenance (objectively measured as WASO and subjectively measured as total sleep time).

Transient Insomnia

Healthy adults were evaluated in a model of transient insomnia (n=436) in a sleep laboratory in a double-blind, parallel-group, single-night trial comparing two doses of Eszopiclone and placebo. Eszopiclone Tablets 3 mg was superior to placebo on measures of sleep latency and sleep maintenance, including polysomnographic (PSG) parameters of latency to persistent sleep (LPS) and WASO.

Chronic Insomnia (Adults and Elderly)

The effectiveness of Eszopiclone Tablets was established in five controlled studies in chronic insomnia. Three controlled studies were in adult subjects, and two controlled studies were in elderly subjects with chronic insomnia.

Adults

In the first study, adults with chronic insomnia (n=308) were evaluated in a double-blind, parallel-group trial of 6 weeks' duration comparing Eszopiclone Tablets 2 mg and 3 mg with placebo. Objective endpoints were measured for 4 weeks. Both 2 mg and 3 mg were superior to placebo on LPS at 4 weeks. The 3 mg dose was superior to placebo on WASO.

In the second study, adults with chronic insomnia (n=788) were evaluated using subjective measures in a double-blind, parallel-group trial comparing the safety and efficacy of Eszopiclone Tablets 3 mg with placebo administered nightly for 6 months. Eszopiclone Tablets was superior to placebo on subjective measures of sleep latency, total sleep time, and WASO.

In addition, a 6-period crossover PSG study evaluating Eszopiclone doses of 1 to 3 mg, each given over a 2-day period, demonstrated effectiveness of all doses on LPS, and of 3 mg on WASO. In this trial, the response was dose related.

Elderly

Elderly subjects (ages 65-86 years) with chronic insomnia were evaluated in two double-blind, parallel-group trials of 2 weeks duration. One study (n=231) compared the effects of Eszopiclone Tablets with placebo on subjective outcome measures, and the other (n=292) on objective and subjective outcome measures. The first study compared 1 mg and 2 mg of Eszopiclone Tablets with placebo, while the second study compared 2 mg of Eszopiclone Tablets with placebo. All doses were superior to placebo on measures of sleep latency. In both studies, 2 mg of Eszopiclone Tablets was superior to placebo on measures of sleep maintenance.

Studies Pertinent to Safety Concerns for Sedative Hypnotic Drugs Next-Day Residual Effects

In a double-blind study of 91 healthy adults age 25- to 40 years, the effects of Eszopiclone Tablets 3 mg on psychomotor function were assessed between 7.5 and 11.5 hours the morning after dosing. Measures included tests of psychomotor coordination that are correlated with ability to maintain a motor vehicle in the driving lane, tests of working memory, and subjective perception of sedation and coordination. Compared with placebo, Eszopiclone Tablets 3 mg was

associated with next- morning psychomotor and memory impairment that was most severe at 7.5 hours, but still present and potentially clinically meaningful at 11.5 hours. Subjective perception of sedation and coordination from Eszopiclone Tablets 3 mg was not consistently different from placebo, even though subjects were objectively impaired.

In a 6-month double-blind, placebo-controlled trial of nightly administered Eszopiclone Tablets 3 mg, memory impairment was reported by 1.3% (8/593) of subjects treated with Eszopiclone Tablets 3 mg compared to 0% (0/195) of subjects treated with placebo. In a 6week adult study of nightly administered Eszopiclone Tablets confusion was reported by 3.0% of patients treated with Eszopiclone Tablets 3 mg, compared to 0% of subjects treated with placebo. In the same study, memory impairment was reported by 1% of patients treated with either 2 mg or 3 mg Eszopiclone Tablets , compared to 0% treated with placebo.

In a 2-week study of 264 elderly insomniacs, 1.5% of patients treated with Eszopiclone Tablets 2 mg reported memory impairment compared to 0% treated with placebo. In another 2-week study of 231 elderly insomniacs, 2.5% of patients treated with Eszopiclone Tablets 2 mg reported confusion compared to 0% treated with placebo.

Withdrawal-Emergent Anxiety and Insomnia

During nightly use for an extended period, pharmacodynamic tolerance or adaptation has been observed with other hypnotics. If a drug has a short elimination half-life, it is possible that a relative deficiency of the drug or its active metabolites (i.e., in relationship to the receptor site) may occur at some point in the interval between each night's use. This is believed to be responsible for two clinical findings reported to occur after several weeks of nightly use of other rapidly eliminated hypnotics: increased wakefulness during the last quarter of the night and the appearance of increased signs of daytime anxiety.

In a 6-month double-blind, placebo-controlled study of nightly administration of Eszopiclone Tablets 3 mg, rates of anxiety reported as an adverse event were 2.1% in the placebo arm and 3.7% in the Eszopiclone Tablets arm. In a 6-week adult study of nightly administration, anxiety was reported as an adverse event in 0%, 2.9%, and 1.0% of the placebo, 2 mg, and 3 mg treatment arms, respectively. In this study, single-blind placebo was administered on nights 45 and 46, the first and second days of withdrawal from study drug. New adverse events were recorded during the withdrawal period, beginning with day 45, up to 14 days after discontinuation. During this withdrawal period, 105 subjects previously taking nightly Eszopiclone Tablets 3 mg for 44 nights spontaneously reported anxiety (1%), abnormal dreams (1.9%), hyperesthesia (1%), and neurosis (1%), while none of 99 subjects previously taking placebo reported any of these adverse events during the withdrawal period.

Rebound insomnia, defined as a dose-dependent temporary worsening in sleep parameters (latency, sleep efficiency, and number of awakenings) compared with baseline following discontinuation of treatment, is observed with short- and intermediate-acting hypnotics. Rebound insomnia following discontinuation of Eszopiclone Tablets relative to placebo and baseline was examined objectively in a 6-week adult study on the first 2 nights of discontinuation (nights 45 and 46) following 44 nights of active treatment with 2 mg or 3 mg. In the Eszopiclone Tablets 2 mg group, compared with baseline, there was a significant increase in WASO and a decrease in sleep efficiency, both occurring only on the first night after discontinuation of treatment. No changes from baseline were noted in the Eszopiclone Tablets 3 mg group on the first night after discontinuation, and there was a significant improvement in LPS and sleep efficiency compared with baseline following the second night of discontinuation. Comparisons of changes from baseline between Eszopiclone Tablets and placebo were also performed. On the first night after discontinuation of Eszopiclone Tablets 2 mg, LPS and WASO were significantly increased and sleep efficiency was reduced; there were no significant differences on the second night. On the first night following discontinuation of Eszopiclone Tablets 3 mg, sleep efficiency was significantly reduced. No other differences from placebo were noted in any other sleep parameter on either the first or second night following discontinuation. For both doses, the discontinuation-emergent effect was mild, had the characteristics of the return of the symptoms of chronic insomnia, and appeared to resolve by the second night after Eszopiclone Tablets discontinuation.

5.4 Non Clinical Toxicological Study

Carcinogenesis, Mutagenesis, Impairment of Fertility *Carcinogenesis*

In a carcinogenicity study in rats, oral administration of Eszopiclone for 97 (males) or 104 (females) weeks resulted in no increases in tumors; plasma levels (AUC) of Eszopiclone at the highest dose tested (16 mg/kg/day) are approximately

80 (females) and 20 (males) times those in humans at the MRHD of 3 mg/day. However, in a 2-year carcinogenicity study in rats, oral administration of racemic Eszopiclone (1, 10, or 100 mg/kg/day) resulted in increases in mammary gland adenocarcinomas (females) and thyroid gland follicular cell adenomas and carcinomas (males) at the highest dose tested. Plasma levels of Eszopiclone at this dose are approximately 150 (females) and 70 (males) times those in humans at the MRHD of Eszopiclone. The mechanism for the increase in mammary adenocarcinomas is unknown. The increase in thyroid tumors is thought to be due to increased levels of TSH secondary to increased metabolism of circulating thyroid hormones, a mechanism not considered relevant to humans.

In a 2-year carcinogenicity study in mice, oral administration of racemic Eszopiclone (1, 10, or 100 mg/kg/day) produced increases in pulmonary carcinomas and carcinomas plus adenomas (females) and skin fibromas and sarcomas (males) at the highest dose tested. The skin tumors were due to skin lesions induced by aggressive behavior, a mechanism not relevant to humans. A carcinogenicity study of Eszopiclone was conducted in mice at oral doses up to 100 mg/kg/day. Although this study did not reach a maximum tolerated dose, and was thus inadequate for overall assessment of carcinogenic potential, no increases in either pulmonary or skin tumors were seen at doses producing plasma levels of Eszopiclone approximately 90 times those in humans at the MRHD of Eszopiclone (and 12 times the exposure in the racemate study).

Eszopiclone did not increase tumors in a p53 transgenic mouse bioassay at oral doses up to 300 mg/kg/day.

Mutagenesis

Eszopiclone was clastogenic in in vitro (mouse lymphoma and chromosomal aberration) assays in mammalian cells. Eszopiclone was negative in the in vitro bacterial gene mutation (Ames) assay and in an in vivo micronucleus assay.

(S)-N-desmethyl Eszopiclone, a metabolite of Eszopiclone, was positive in in vitro chromosomal aberration assays in mammalian cells. (S)-N-desmethyl Eszopiclone was negative in the in vitro bacterial gene mutation (Ames) assay and in an in vivo chromosomal aberration and micronucleus assay. Impairment of Fertility

Oral administration of Eszopiclone to rats prior to and during mating, and continuing in females to day 7 of gestation (doses up to 45 mg/kg/day to males and females or up to 180 mg/kg/day to females only) resulted in decreased fertility, with no pregnancy at the highest dose tested when both males and females were treated. In females, there was an increase in abnormal estrus cycles at the highest dose tested. In males, decreases in sperm number and motility and increases in morphologically abnormal sperm were observed at the mid and high doses. The no-effect dose for adverse effects on fertility (5 mg/kg/day) is 16 times the MRHD on a mg/m2 basis.

6.0 Pharmaceutical particulars

6.1 List of excipients

Tablets core:

Lactose Monohydrate USP-NF (Pharmatose 200 M), Microcrystalline Cellulose, USP-NF (Avicel PH 102), Anhydrous Dibasic Calcium Phosphate, USP (A-Tab), Croscarmellose Sodium, USP-NF (Ac-Di-SoL), Colloidal Silicon Dioxide, USP-NF (Aerosil 200), Magnesium Stearate, USP-NF (LIGAMED MF-2-V), Tablet coating

Coating agent composition: Opadry White 03G58632:

%w/w	Ingredients/Compendial Reference	Grade/Dye Strength	E Number	CFR Reference	CI Number
62.500	HPMC 2910/HYPROMELLOSE (USP, Ph.Eur, JP)	6 cP	E464	172.874	-
23.250	TITANIUM DIOXIDE (USP,FCC, Ph.Eur, JP)	-	E171	73.575,73.1575	77891
8.000	MACROGOL/PEG (NF, FCC, Ph.Eur, JECFA, JP)	MW 3350, MACROGO L 4000 JP	E1521	172.820	-
6.250	TRIACETIN (USP, FCC, Ph.Eur, JPE)	-	-	184.1901	-

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

36 Months

6.4 Special precautions for storage Store below 30°C.

6.5 Nature and contents of container

10’s Alu/Alu Blister

7. Marketing authorization holder

HETERO LABS LIMITED, INDIA.

Manufactured by:

HETERO LABS LIMITED

Unit-V, TSIIIC Formulation SEZ, Survey No. 411, 425, 435 & 458, Polepally village, Jadcherla Mandal,
Mahaboob Nagar (Dist) – 509301, Telangana. India

8. Marketing Authorization Numbers: H2025/CTD11478/22711

9. Date of first registration /renewal of the registration: Oct 27, 2025

10. Date of revision of text: Mar 19, 2026